Full-Time

Associate Director

Investor Relations

5AM Ventures

5AM Ventures

11-50 employees

Venture capital investing in life-science innovations

No salary listed

Boston, MA, USA

In Person

On-site role in Boston, Massachusetts.

Category
Business & Strategy (1)
Required Skills
Data Governance
Excel/Numbers/Sheets

Get referred to 5AM Ventures

See people who can refer or advise you

Requirements
  • 8-10 years of experience in investor relations, venture capital, private equity, or fund operations, with increasing scope and ownership.
  • Advanced CRM expertise, including system optimization, workflow creation, and data governance; Dynamo experience strongly preferred.
  • Deep knowledge of fundraising strategy, LP engagement, due diligence processes, and investor onboarding frameworks.
  • Demonstrated ability to lead complex, cross-functional initiatives across Finance, Legal, Operations, and external partners.
  • Exceptional organizational and program management skills, with the ability to build scalable processes and manage competing priorities.
  • Sophisticated communication skills—capable of delivering clear, compelling materials and presenting effectively to internal leadership and external LPs.
  • Experience overseeing compliance-reviewed, investor-facing materials, quarterly reporting, and capital activity communications.
  • Proven ability to represent the firm with credibility in investor meetings, diligence discussions, and strategic partnership conversations.
  • High technical proficiency across CRM systems, Excel/modeling for IR needs, data rooms, Zoom, CMS platforms, and professional communication tools; comfortable evaluating and improving toolsets.
Responsibilities
  • Own the CRM (Dynamo) as the source of truth for all investor, prospect, and portfolio company data.
  • Manage fundraising pipelines for the Opportunities and Ventures funds, ensuring accuracy, timely updates, and visibility for senior leadership.
  • Oversee the monthly import and reconciliation of fund balances and transactions from fund administrators (e.g., HedgeServ).
  • Maintain high-quality investor records, including firm, contact, and opportunity-level data.
  • Track investor touchpoints, meeting notes, next steps, and event participation to support data-driven IR strategy.
  • Generate recurring and ad-hoc reports for IR, Finance, Legal, and Investment teams.
  • Lead the setup, organization, and ongoing management of data rooms for fundraising and investor reporting.
  • Ensure all materials are uploaded, archived, and version-controlled across funds.
  • Manage investor access, onboarding, and permissions.
  • Maintain and update data room home pages and folder structures to support LP usability.
  • Maintain an accurate, real-time view of the fundraising pipeline; prepare pipeline summaries and insights for leadership.
  • Join select investor meetings to support content updates, pitchbook revisions, and follow-up execution.
  • Triage LP requests, coordinating responses across Finance, Legal, and the Investment Team.
  • Partner with senior IR leadership on DDQs, RFPs, questionnaires, and diligence materials.
  • Collaborate on drafting and updating Venture fundraising collateral and data room content.
  • Support the design and execution of fundraising roadshows for Opps and Ventures, including coordinating outreach, materials, schedules, and follow-ups.
  • Manage relationship with European placement agents to support international investor pipeline development.
  • Assist with investor onboarding: Opportunities Fund: coordinate between LPs and fund admin to ensure smooth onboarding; Venture Fund: support development of an online sub-document process and manage LP workflow.
  • Manage the creation, updating, formatting, and review process for all investor-facing materials, including: Pitchbooks, Investor-specific presentations, Monthly Tear Sheets, Quarterly Letters, Webinar and Annual Meeting decks, Press releases and conference materials; Ensure all materials meet compliance standards, include required disclosures, and are properly logged and archived.
  • Oversee website updates, including team pages, portfolio company listings, press releases, and compliance-driven disclosures.
  • Partner with external developers on site enhancements and potential rebrand initiatives.
  • Manage the firm’s LinkedIn presence, coordinating with Compliance and supporting content development.
  • Lead logistics and material creation for the Annual LP Meeting and other major investor events.
  • Plan and execute webinars, including branding, registration, speaker coordination, and post-event follow-up.
  • Manage hybrid event setups and vendor relationships to ensure secure and seamless participation.
  • Maintain event materials, communications, contact lists, and timelines.

5AM Ventures is an investment firm focused on backing advanced life science innovations. It diversifies its bets across biopharmaceutical therapeutics and platform technologies, investing within multiple therapeutic areas and modalities. Its approach targets opportunities built on innovative platform platforms, corporate spin-offs, and products with shorter development timelines. The firm’s “product” is providing capital, strategic guidance, and resources to portfolio companies to help them reach clinically or commercially viable milestones faster. Unlike some investors that emphasize a single niche, 5AM differentiates itself by breadth across life science sectors and a focus on technologies with the potential for quicker development cycles. The firm’s goal is to create value by supporting responsible, science-driven progress in life sciences and helping portfolio companies advance promising therapies and platforms to patients and markets.

Company Size

11-50

Company Stage

N/A

Total Funding

$9.2B

Headquarters

Menlo Park, California

Founded

2002

Get referred to 5AM Ventures

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Recent investments include Latigo Bio, Nouscom, Mendra, and Kinaset Therapeutics.[4][12]
  • The firm supports 101 portfolio companies, providing broad deal flow and follow-on options.[3]
  • Its fund structure supports discovery through public-market support across development stages.[14]

What critics are saying

  • Biotech concentration exposes 5AM to clinical failures and long development timelines.[3][16]
  • Public holdings like Skye, Entrada, and Pharvaris create mark-to-market volatility.[16]
  • Crowded early-stage therapeutics markets pressure differentiation and exit outcomes for portfolio companies.[4]

What makes 5AM Ventures unique

  • 5AM Ventures is a 2002-founded life science VC with dedicated early-stage and opportunities funds.[1]
  • It backs breakthrough therapeutics, platform biotechs, and adjacent life-science tools.[1][18]
  • Its 2022 capital base included $450M for early-stage investing and $300M later-stage.[14]

Help us improve and share your feedback! Did you find this helpful?

Benefits

Wellness Program

Mental Health Support

Conference Attendance Budget

Professional Development Budget

Remote Work Options

Hybrid Work Options

Flexible Work Hours

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Holidays

PTO/vacation is mentioned? Not explicitly; will not assume beyond listed items

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Fertility Treatment Support

Family Planning Benefits

Adoption Assistance

Parental Leave

Stock Options

Company Equity

Education allowance

Professional Certification Support

Tuition Reimbursement

Mentorship Program

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Wellness Program

Mental Health Support

Company News

Stock Titan
Jan 30th, 2026
Biotech ALX Oncology raises $150M to fund cancer drug trials

Offering prices 76.9M shares at $1.57 plus pre-funded warrants, raising ~$150M to advance ALX Oncology’s evorpacept and ALX2004 trials.

Business Wire
Jan 23rd, 2026
Mendra Launches with $82 Million Series A to Acquire, Develop, and Commercialize Therapeutics for High Unmet Need Rare Diseases

Mendra, Inc. (“Mendra”), a biopharmaceutical company built to advance promising therapies for rare disease medicines, utilizing artificial intelligence (AI),...

Kinaset Therapeutics
Jan 12th, 2026
Kinaset Therapeutics Announces $103 Million Oversubscribed Series B Financing to Advance Novel, Inhaled Therapeutic Candidate for Respiratory Diseases — Kinaset Therapeutics

Kinaset Therapeutics Announces FDA Clearance of IND Application for frevecitinib (KN-002) in Asthma Treatment

Castle Placement
Jan 8th, 2026
Top 10 Pharma Drug Discovery Delivery Capital Raises and Investors in the U.S. - November 16th - December 31st, 2025

Top 10 Pharma Drug Discovery Delivery capital raises and investors in the U.S. - november 16th - december 31st, 2025. Several interesting transactions closed in the Pharma Drug Discovery Delivery sector over the past month. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me. * Surmodics, performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays, was acquired by GTCR through a $626.85 million public-to-private LBO. * Aeovian Pharmaceuticals, biotechnology therapies that address inflammatory and degenerative diseases, raised $55 million of Series B venture funding in a deal led by CTI Life Sciences Fund and Luma Group. * Imbria Pharmaceuticals, novel therapies for patients with life-altering cardiometabolic disorders, raised $66.70 million of Series B venture funding in a deal led by Deep Track Capital. * Mend, clinical nutritional products that assist people in healing and living a quality life, raised $20.45 million of Series A venture funding led by S2G Investments. * ProLynx, ultra-long-acting medicines for obesity and other metabolic diseases, raised $70 million through a combination of Series A-1, Series A-2, and Series A-3 venture funding in a deal led by OrbiMed and 5AM Ventures. * Vitrivax, thermostable vaccine formulations that eliminate barriers to global vaccination, raised $29.43 million through a combination of Series B-1 and Series B-2 venture funding in a deal led by RA Capital Management and Adjuvant Capital. * Addition Therapeutics, biotech and pharmaceutical research company that transforms genetic medicine, raised $106.5 million of venture funding from Abingworth, SR One Capital Management and Osage University Partners. * Quarry Thera, proximity-driven therapeutics that overcomes limitations in conventional drug modalities, raised $32 million of Series A venture funding from Eli Lilly, Yosemite and Canaan Partners. * Solve Therapeutics, drug development platform that develops novel antibody-drug conjugates, raised $321 million of Series A venture funding in a deal led by Yosemite. * Juniper Biosciences, therapeutic and diagnostic agents intended for precision healthcare and disease management purposes, raised $40 million of seed funding in a deal led by Nova Capital. Diana ruddy. Managing director. Please contact me if you have any questions or would like to discuss your capital raise:

BioPharma Dive
Dec 11th, 2025
Prolynx banks $70M for longer-lasting obesity drugs

Using a novel linker technology, the startup is developing versions of incretin and non-incretin therapies that can be administered monthly or quarterly.